A highly sensitive quantitative real-time pcr assay for determination of mutant jak2 exon 12 allele burden

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Kjær, Lasse ^a   Westman, Maj ^b   Riley, Caroline Hasselbalch ^a   Høgdall, Estrid ^a   Bjerrum, Ole Weis ^b   Hasselbalch, Hans ^c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c ROSKILDE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; JANUS KINASE 2;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CELL COUNT; CHRONIC MYELOPROLIFERATIVE NEOPLASM; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; EXON; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE; GENE DOSAGE; GENE DUPLICATION; GENE FREQUENCY; GENE IDENTIFICATION; GRANULOCYTE; HETEROZYGOTE DETECTION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN CELL; INDEL MUTATION; JANUS KINASE 2 GENE; LIMIT OF DETECTION; LYMPHOCYTE COUNT; MALE; MONOCYTE; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; POLYMERASE CHAIN REACTION; PROGNOSIS; REAL TIME QUANTITATIVE POLYMERASE CHAIN REACTION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; GENETICS; METHODOLOGY; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENE FREQUENCY; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; REAL-TIME POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84857766125     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033100     Document Type: Article

References (35)

1. Vardiman JW, Harris NL, Brunning RD, (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100: 2292-2302.
2. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061.
3. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144-1148.
4. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779-1790.
5. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387-397.
6. Zhao R, Xing S, Li Z, Fu X, Li Q, et al. (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280: 22788-22792.
7. Dawson MA, Curry JE, Barber K, Beer PA, Graham B, et al. (2010) AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders. Br J Haematol 150: 46-57.
8. Hexner EO, Serdikoff C, Jan M, Swider CR, Robinson C, et al. (2008) Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111: 5663-5671.
9. Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, et al. (2007) TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 21: 1658-1668.
10. Lasho TL, Tefferi A, Hood JD, Verstovsek S, Gilliland DG, et al. (2008) TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia 22: 1790-1792.
11. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, et al. (2010) Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 115: 1131-1136.
12. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, et al. (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363: 1117-1127.
13. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, et al. (2011) Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29: 789-796.
14. Barosi G, Rosti V, Vannucchi AM, (2011) Therapeutic approaches in myelofibrosis. Expert Opin Pharmacother 12: 1597-1611.
15. Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T, et al. (2011) JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia 25: 218-225.
16. Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, et al. (2011) Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 117: 5857-5859.
17. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, et al. (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 21: 1952-1959.
18. Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, et al. (2010) A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 24: 1574-1579.
19. Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, et al. (2006) The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 106: 631-635.
20. Plo I, Nakatake M, Malivert L, de Villartay JP, Giraudier S, et al. (2008) JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 112: 1402-1412.
21. Hasselbalch HC, Larsen TS, Riley CH, Jensen MK, Kiladjian JJ, (2011) Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives. Curr Drug Targets 12: 392-419.
22. Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, et al. (2011) Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 117: 2813-2816.
23. Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N, (2007) The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 136: 745-751.
24. Lippert E, Girodon F, Hammond E, Jelinek J, Reading NS, et al. (2009) Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica 94: 38-45.
25. Scott LM, (2011) The JAK2 exon 12 mutations: A comprehensive review. Am J Hematol 86: 668-676.
26. Carillo S, Henry L, Lippert E, Girodon F, Guiraud I, et al. (2011) Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of jak2 exon 12 mutations-clinical relevance in the monitoring of polycythemia. J Mol Diagn 13: 263-270.
27. Jones AV, Cross NC, White HE, Green AR, Scott LM, (2008) Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. Haematologica 93: 1560-1564.
28. Rapado I, Grande S, Albizua E, Ayala R, Hernandez JA, et al. (2009) High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms. J Mol Diagn 11: 155-161.
29. Laughlin TS, Moliterno AR, Stein BL, Rothberg PG, (2010) Detection of exon 12 Mutations in the JAK2 gene: enhanced analytical sensitivity using clamped PCR and nucleotide sequencing. J Mol Diagn 12: 278-282.
30. Schnittger S, Bacher U, Haferlach C, Geer T, Muller P, et al. (2009) Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera. Haematologica 94: 414-418.
31. Theocharides A, Passweg JR, Medinger M, Looser R, Li S, et al. (2008) The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica 93: 1890-1893.
32. Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC, (2008) Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow. Leukemia 22: 194-195.
33. Li S, Kralovics R, De Libero G, Theocharides A, Gisslinger H, et al. (2008) Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood 111: 3863-3866.
34. Campbell PJ, Green AR, (2006) The myeloproliferative disorders. N Engl J Med 355: 2452-2466.
35. Vossen RH, Aten E, Roos A, den Dunnen JT, (2009) High-resolution melting analysis (HRMA): more than just sequence variant screening. Hum Mutat 30: 860-866.